<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR26">
 <label>26.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hirayama</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Honarpour</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Yoshida</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Yamashita</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Wasserman</surname>
    <given-names>SM</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study</article-title>
  <source>Circ J</source>
  <year>2014</year>
  <volume>78</volume>
  <fpage>1073</fpage>
  <lpage>1082</lpage>
  <pub-id pub-id-type="doi">10.1253/circj.CJ-14-0130</pub-id>
  <?supplied-pmid 24662398?>
  <pub-id pub-id-type="pmid">24662398</pub-id>
 </element-citation>
</ref>
